(Q41844119)

13 October 2017

Bone building with bortezomib (English)

1 reference

13 October 2017

G David Roodman

1

1 reference

PMC publication ID

2213378

13 October 2017

language of work or name

English

0 references

publication date

1 February 2008

1 reference

Journal of Clinical Investigation

13 October 2017

1 reference

13 October 2017

118

1 reference

13 October 2017

2

1 reference

13 October 2017

462-464

1 reference

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

13 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Pathophysiology of multiple myeloma bone disease

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Molecular and cellular mechanisms of the anabolic effect of intermittent PTH

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Myeloma bone disease and proteasome inhibition therapies.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Response to bortezomib and activation of osteoblasts in multiple myeloma

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

E3 Ubiquitin Ligase Smurf1 Mediates Core-binding Factor α1/Runx2 Degradation and Plays A Specific Role in Osteoblast Differentiation

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

RANK ligand and osteoprotegerin in myeloma bone disease.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Bortezomib inhibits human osteoclastogenesis.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2213378

A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo

2 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18219395

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18219395

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1172/JCI34734

1 reference

13 October 2017

1 reference

PMC publication ID

2213378

13 October 2017

PubMed publication ID

18219395

1 reference

PMC publication ID

2213378